In the Casselholm study, EYLEA® significantly reduced treatment burden vs. ranibizumab while improving vision1

EYLEA (n=22) significantly reduced injection frequency by 24% vs. ranibizumab (n=23) in a treat-and-extend (T&E) regimen1

  • 67% of the whole cohort of patients (n=43) achieved a visual gain of ≥15 letters1
  • The majority of EYLEA-treated patients had a 12-week injection interval while the majority of ranibizumab patients needed follow-up with an interval of 6 weeks or longer1
Mean BCVA gain at 18 months

The present study shows that in patients with ME secondary to CRVO, the use of aflibercept significantly reduces injection frequency compared with ranibizumab in a treat-and extend regimen. Thus, treatment burden can be reduced without negative impact on visual outcome.

BCVA, best-corrected visual acuity; CI, confidence interval; ETDRS, Early Treatment Diabetic Retinopathy Study; ITT, intention-to-treat; PRN, pro re nata; T&E, treat-and-extend; ME, Macular Edema.

Reference

  1. Casselholm de Salles M, Amrén U, Kvanta A, et al. Injection frequency of aflibercept versus ranibizumab in a treat-and-extend regimen for central retinal vein occlusion. Retina. 2018;0:1-7.